XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Assets and Liabilities Measured at Fair Value (Details)
$ in Thousands
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Assets:    
Fair value of assets $ 365,490 $ 311,700
Liabilities:    
Contingent consideration payable 28,100 25,400
Deferred compensation plan liability 2,996 2,258
Fair value of liabilities 31,096 27,658
T B200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Callidus Biopharma Inc    
Liabilities:    
Contingent consideration payable $ 27,600  
T B200 Pompe Program | Minimum | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Callidus Biopharma Inc    
Liabilities:    
Discount rate 0.710  
T B200 Pompe Program | Maximum | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Callidus Biopharma Inc    
Liabilities:    
Discount rate 1.000  
Commercial paper    
Assets:    
Fair value of assets $ 82,655 79,803
Asset-backed securities    
Assets:    
Fair value of assets 52,101 30,287
Corporate debt securities    
Assets:    
Fair value of assets 227,399 199,012
Money market funds    
Assets:    
Fair value of assets 3,335 2,598
Level 2    
Assets:    
Fair value of assets 365,490 311,700
Liabilities:    
Contingent consideration payable 0 0
Deferred compensation plan liability 2,996 2,258
Fair value of liabilities 2,996 2,258
Convertible debt, fair value 531,200  
Level 2 | Commercial paper    
Assets:    
Fair value of assets 82,655 79,803
Level 2 | Asset-backed securities    
Assets:    
Fair value of assets 52,101 30,287
Level 2 | Corporate debt securities    
Assets:    
Fair value of assets 227,399 199,012
Level 2 | Money market funds    
Assets:    
Fair value of assets 3,335 2,598
Level 3    
Liabilities:    
Contingent consideration payable 28,100 25,400
Deferred compensation plan liability 0 0
Fair value of liabilities $ 28,100 $ 25,400
Level 3 | T B200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability Weighted Discounted Cash Flow | Discount Rate | Callidus Biopharma Inc    
Liabilities:    
Discount rate 0.10